CURRICULUM VITAE

Christy A. Schmeck CMA, CCRC

Certified Clinical Research Coordinator
OSHA Compliance Officer
WR-ClinSearch
6035 Shallowford Road Suite 109
Chattanooga, TN 37421
Phone: 423-698-4584
Fax: 423-698-4577
cschmeck@clinsearch-us.com

Education

1999-2001 City College Gainesville, Fl

- A.S. in Medical Office Administration
- A.S. in Medical Assisting
- National Certified Medical Assistant
- Graduated Summa Cum Laude
- Certified First Responder

Professional Experience

September 2009-Present	ACRP Certified Clinical Research Coordinator OSHA Compliance Officer WR-ClinSearch, Chattanooga, TN
2008-2009	Medical Assistant Southeastern Women's Health, Gainesville, FL
2001-2008	Medical Assistant Gainesville Family Physicians, Gainesville, FL

Continuing Education

ACRP	Sep2012 Oct2014 Nov2016	Bioclinica	02Nov2011
IATA	10Sep2009 06Sep2011 24Sep2013 14Oct2015 28Sep2017	Oracle ERT Datalabs Trium	21Sep2009 28Sep2009 11Jul2012 03Feb2016
CITI	16Nov2009 14Oct2010 19Oct2011 10Sep2012 03Jul2013 22Jul2015 17Jul2017	Medidata Inform	02Nov2009 04Nov2010 27Feb2012 29Sep2009 29Aug2011
OSHA	08Apr2010 30Mar2011 24Apr2012 17Apr2013 20Apr2014 02May2015 04Jan2016	eClinical Spirometry Sphygmacor C-SSRS Fibroscan	Jul2013 18Mar2010 02Feb2012 23Sep2015 16Jan2017
CPR	18Nov2010 04Dec2012 18Nov2014 15Nov2016		

Research Experience

Gynecology

- A phase 2, 16 week, multicenter, randomized, double blind placebo controlled, parallel group proof of concept study evaluating the efficacy and safety of Tanezumab for the treatment of pain associated with Endometriosis

- A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NBI-56418 in subjects with Endometriosis

Endocrinology

- A randomized, double-blind, placebo and active controlled parallel group, multicenter study to determine the efficacy and safety of Albiglutide when used in combination with Metformin compared with Metformin plus Sitagliptin, Metformin plus Glimepiride, and Metformin plus placebo in subjects with Diabetes Mellitus Type II

- A randomized, open-label, parallel group, multicenter study to determine the efficacy and long term safety of Albiglutide compared with Insulin in subjects with Diabetes Mellitus Type II

- A randomized, double-blind, placebo and active controlled, parallel group, multicenter study to determine the efficacy and safety of Albiglutide administered in combination with Metformin and Glimepride compared with Metformin plus Glimerpiride and placebo and with Metformin plus Glimepriride and Pioglitazone in subjects with Diabetes Mellitus Type II

- A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of Dutagliptin in patients with Diabetes Mellitus Type II on background treatment with Glimepiride with or wtihout Metformin

- A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of Dutagliptin in patients with Diabetes Mellitus Type II on background treatment with Pioglitazone

- A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of LX4211 in combination with Metformin in subjects with Diabetes Mellitus Type II

- A phase 2, randomized, placebo controlled, double blind, parallel-group, multi-center study to determine the safety and efficacy of 25 mg and 50 mg of TAK875 in combination with Sitagliptin 100 mg in subjects with Diabetes Mellitus Type II.

- A randomized, double-blind, phase 3 proof of concept study to evaluate the efficacy and safety of TAK-491 compared to placebo when used in combination with Metformin in subjects with Hypertension and Diabetes Mellitus Type II

- A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes

Gastroenterology

- A dose-response efficacy and safety study of Arbaclofen Placarbil as adjunctive therapy in subjects with Gastroesophageal Reflux Disease who are incomplete responders to a proton pump inhibitor

- A randomized, double-blind, placebo controlled, multi-center phase 2b dose finding study to assess the effect on GERD symptoms, safety and tolerability during four weeks treatment with AZD3355 in doses 60 mg, 120 mg, 180 mg and 240 mg twice daily as add-on treatment to a PPI in patients with GERD that are partial responders to PPI treatment

- A phase 3, randomized, double-blind, placebo-controlled, parallel-group trial of Linaclotide administered orally for 26 weeks in patients with Irritable Bowel Syndrome Constipation Predominant

- An open-label, long-term safety study of oral Linaclotide administered to patients with Chronic Constipation or Irritable Bowel Syndrome Constipation Predominant

- A phase 2b, double-blind, randomized, placebo-controlled, multi-centre, dose-finding efficacy and safety study of range of doses of a3309 in patients with Chronic Idiopathic Constipation

- A phase 3, randomized, double-blind, dose-response, stratified, placebo-controlled study evaluating the safety and efficacy of SPD476 versus placebo over 104 weeks in the prevention of recurrence of diverticulitis

- A randomized, open-label, blinded-endpoint, parallel-group trial of GI safety of Celecoxib compared with non-selective nonsteroidal anti-inflammatory drugs in Osteoarthritis patients

- A 6-month, phase 3, randomized, double-blind, parallel-group, controlled, multi-center study to evaluate the incidence of gastric ulcers following administration of either PA32540 or enteric coated Asprin 325 mg in subjects who are at risk for developing aspirin-associated ulcers

- A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multicenter study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with Irritable Bowel Syndrome Diarrhea Predominant

- A 12- week, randomized, double-blind, placebo-controlled study of Asimadoline in subjects with Irritable Bowel Syndrome Diarrhea Predominant

- A double-blind, dose response, randomized, placebo-controlled, parallel group, multi-centre phase 3 clinical study on the efficacy and tolerability of Mesalazine Granules vs. placebo for the prevention of recurrence of Diverticulitis

- Procurement of blood samples from IBD, GI controls and healthy volunteer subjects for use in the development of gastrointestinal disease tests

- A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of oral Methylnaltrexone for the treatment of Opioid Induced Constipation in subjects with chronic, non malignant pain

- A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NKTR-118 in patients with non-cancer related pain and Opioid Induced Constipation

- A randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of different doses of Larazotide Aacetate for the treatment of Celiac Disease.

- A double blind, randomized, placebo-controlled, parallel group, multi-site study to evaluate the clinical equivalence of lubiprostone 24 mcg capsules with amitiza 24 mcg capsules in the treatment of chronic idiopathic constipation

- A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of RDX5791 for the treatment of Irritable Bowel Syndrome Constipation Predominant

- A randomized, double-blind, placebo-controlled multicenter phase 2 study to evaluate the safety and efficacy and dose response of 28 days of once-daily dosing of the oral Motilin Receptor Agonist GSK962040, in Diabetes Mellitus Type I and Type II male and female subjects with Gastroparesis

- A phase 2, multi-center, randomized, double-blind, placebo-controlled, multiple-dose study to determine the safety and efficacy of orally administered LX1033 in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

- A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant Irritable Bowel Syndrome.

- A phase 1, a randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of Nexvax2 in patients with Celiac Disease.

- A single center, randomized, single blind pilot study. To determine the safety, efficacy, and tolerability of a split-dose regimen of crystalline lactulose for cleansing of the colon as a preparation for colonoscopy.

- A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Anucort HC (Hydrocortisone Acetate) 25mg Rectal Suppositories in the treatment of Symptomatic Internal Hemorrhoids

- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet

- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group,Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients with Diabetic Gastroparesis

- A Phases 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients with Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

- A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy

- A Phase 2a Study to Evaluate the Effect of IW-3718 Administered Orally for 4 Weeks in Patients With GERD Not Completely Responsive to Proton Pump Inhibitors

- A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy

- A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
- An Open Label, Long Term Safety and Tolerability Study of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

- A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

- An Open Label Long-Term Safety Study of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

- Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

- A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Mongersen GED-0301 Maintenance Therapy in Subjects With Crohn's Disease

Hepatology

- A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis

- CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis

- A Phase 2, Randomized, Double Blind, Placebo Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects With Nonalcoholic Steatohepatitis

- A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis

- A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (**IDN-6556-12**), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis

- A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)

- Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

---

- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

- AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

- A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of Pf-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease

Cardiovascular

- A six-month, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to determine the efficacy and safety of 300 and 450 mg/day Transdermal Testosterone in female patients with low ejection fraction and symptomatic Heart Failure

- A phase 3, open-label, randomized, long-term comparison of the safety and tolerability of TAK -491 plus Chlorthalidone fixed-dose combination vs. Olmesartan Medoxomil-Hydrochlorothiazide fixed-dose combination in subjects with Essential Hypertension

- A multicenter, randomized, active-control, phase 3b study to evaluate the cardiovascular safety of Febuxostat and Allopurinol in subjects with Gout and Cardiovascular Comorbidities.

Neurological

- A randomized, double-blind, placebo-controlled, parallel-group, phase 3 study of MAP0004 in adult migraines for a single migraine followed by open label extensions to 26/52 weeks

- Safety and tolerability study comparing Sodium Oxybate given as an oral solution to a single blinded combination of oral tablets plus oral solution in subjects with Fibromyalgia

- A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Genitourinary

- A multi-centre, randomized, double-blind, placebo-controlled, parallel-group trial with an open -label extension to demonstrate the efficacy and safety of Desmopressin orally disintegrating tablets for the treatment of Nocturia in adult male

Dermatology

- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis

- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis

- An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials

- Double-Blind Randomized Vehicle Controlled Study Evaluating Safety and Bioequivalence of Generic Pimecrolimus Cream 1% and Elidel® Comparing Both Active Treatments to a Vehicle Control in Treatment of Mild to Moderate Atopic Dermatitis

Signature: Wendy Lehmeck **Date:** 05/04/2017